Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended March 31, 2000
Business Overview: BD operates through three principal segments: BD Medical Systems, BD Biosciences, and BD Preanalytical Solutions. The company manufactures medical devices, diagnostic products, and preanalytical solutions.
Key Financial Metrics
| Metric | Q1 2000 (3 Months) | Q1 1999 (3 Months) | YTD 2000 (6 Months) | YTD 1999 (6 Months) |
|---|---|---|---|---|
| Revenues | $925.1 million | $874.0 million | $1,784.3 million | $1,642.9 million |
| Operating Income | $149.9 million | $144.4 million | $271.5 million | $255.3 million |
| Net Income | $119.2 million | $90.1 million | $194.5 million | $166.3 million |
| Diluted EPS | $0.45 | $0.34 | $0.74 | $0.63 |
| Operating Margin | 16.2% | 16.5% | 15.2% | 15.5% |
| Gross Margin | 48.8% | 50.9% | 48.2% | 50.4% |
| Cash from Operations (YTD) | $267.2 million (vs. $125.1 million prior year) | |||
| Total Debt | $1.55 billion (Short-term: $730M; Long-term: $820M) | |||
| Cash & Equivalents | $65.1 million (as of March 31, 2000) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 6% for the quarter and 9% year-to-date. Growth was driven by BD Biosciences (+13% Q/Q) and BD Preanalytical Solutions (+9% Q/Q), while BD Medical Systems grew 1%.
- Profitability: Net income rose 32% year-over-year for the quarter. However, gross margins declined due to a less profitable product mix, higher production costs for advanced protection devices, and a $13 million product recall charge.
- One-Time Items:
- Investment Gain: A $33 million pre-tax gain on the sale of an investment significantly boosted "Other income, net."
- Product Recall: A voluntary recall of BD Insyte AutoGuard IV catheters resulted in $13 million in costs recorded in Cost of Products Sold.
- Currency Impact: A strengthened dollar reduced reported revenues by an estimated $18 million for the quarter and $29 million for the six-month period.
Guidance, Outlook, and Risks
- Capital Expenditures: Management expects fiscal 2000 capital spending to be approximately $375 million, reflecting increased investment in manufacturing capacity for advanced protection devices.
- Product Recall Status: The BD Insyte AutoGuard recall is resolved; manufacturing processes were adjusted, and shipments resumed in the third quarter. Management does not expect further revenue impact from this event.
- Year 2000 Compliance: The company has completed all necessary modifications for Year 2000 compliance, incurring approximately $17 million in total costs. No significant disruptions were experienced.
- Legal Proceedings: BD is a defendant in approximately 365 product liability lawsuits regarding natural rubber latex and 11 cases regarding needle-stick injuries. Management believes the aggregate outcome will not have a material impact on financial condition.
- Accounting Changes: The company is evaluating the impact of SFAS No. 133 (Derivatives) and SAB No. 101 (Revenue Recognition), with adoption required by the first quarter of fiscal 2001.
Investor Verification Checklist
- Recall Costs: Verify the $13 million recall charge impact on gross margin and confirm no further liability exists for the BD Insyte AutoGuard product.
- Investment Gain: Assess the sustainability of earnings given the $33 million one-time gain on investment sales.
- Margin Compression: Monitor gross margin trends as the company scales up production of advanced protection devices, which currently carry higher costs.
- Currency Exposure: Evaluate the impact of foreign exchange rates on international revenue, which represented a significant portion of total sales.
- Debt Levels: Review the debt-to-capital ratio (45.1%) and the company's ability to service $1.55 billion in total debt amidst increased capital spending.